Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evolus, Inc.
Report date October 16, 2023 · Filed October 18, 2023
Section 16 reporting ended · disclosed 2023-10-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.00001 par value per shareSEC Table I · non-derivative | Direct | 3,381,326 |
Reported balance
After 2023-10-16 transaction · row 1
1 source rowRow 1 · 2023-10-16 · Sale · Disposed 1,690,663 · Balance 3,381,326 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2023 Filed Oct 18, 2023 20:21 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 1,690,663 | $7.50 | $12,679,972.50 |
DisclosureSEC source: 0001387131-23-012379 · ownership.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · Former 10% Owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,381,326 Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 01:10 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 2,187,511 | $8.50 | $18,593,843.50 |
DisclosureSEC source: 0001387131-23-001621 · ownership.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,071,989 Read SEC document |
| January 20, 2023 Filed Feb 6, 2023 21:18 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 37,043 | $11.04 | $408,954.72 |
DisclosureSEC source: 0001387131-23-001468 · ownership.xml · nonDerivative · entry 3 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,259,500 F1 · date: Inadvertently filed late due to an administrative error. F4 · ownership.nature: The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:12 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 38,304 | $8.99 | $344,418.08 |
DisclosureSEC source: 0001387131-22-010336 · eols-form4_100622.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.95 to $9.02, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 20:18 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 6,848 | $8.95 | $61,289.60 |
DisclosureSEC source: 0001839882-22-023112 · eols-form4_100522.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,297,804 Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 20:10 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 24,000 | $10.34 | $248,104.80 |
DisclosureSEC source: 0001387131-22-009830 · eols-form4_091422.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,304,652 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.17 to $10.43, inclusive. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:10 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 73,000 | $10.27 | $749,673.50 |
DisclosureSEC source: 0001387131-22-009830 · eols-form4_091422.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,328,652 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.10 to $10.54, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnotes (1) and (2) to this Form 4. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 21:45 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 20,700 | $10.53 | $217,910.97 |
DisclosureSEC source: 0001387131-22-009717 · eols-form4_090822.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,401,652 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.45 to $10.70, inclusive. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 21:45 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 15,300 | $10.39 | $158,979.24 |
DisclosureSEC source: 0001387131-22-009717 · eols-form4_090822.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,422,352 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.34 to $10.50, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form4. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:08 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock, $0.00001 par value per share | 26,000 | $13.28 | $345,360.60 |
DisclosureSEC source: 0001387131-22-008344 · eols-form4_082721.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,437,652 Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:19 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 51,000 | $10.93 | $557,567.70 |
DisclosureSEC source: 0001387131-21-009158 · eols-form4_082721.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,463,652 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:21 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 66,000 | $11.02 | $727,405.80 |
DisclosureSEC source: 0001387131-21-009024 · eols-form4_082521.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,412,652 Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:21 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 44,000 | $11.12 | $489,385.60 |
DisclosureSEC source: 0001387131-21-009024 · eols-form4_082521.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,346,652 Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 20:21 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 72,219 | $11.17 | $807,032.88 |
DisclosureSEC source: 0001387131-21-008933 · medytox-form4_082321.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,302,652 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:21 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 69,781 | $11.03 | $769,775.15 |
DisclosureSEC source: 0001387131-21-008933 · medytox-form4_082321.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,230,433 Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 20:26 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 48,000 | $10.56 | $506,697.60 |
DisclosureSEC source: 0001387131-21-008879 · medytox-form4_081921.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,160,652 Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:26 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 55,000 | $10.51 | $578,110.50 |
DisclosureSEC source: 0001387131-21-008879 · medytox-form4_081921.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112,652 Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 20:15 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 45,000 | $10.54 | $474,075.00 |
DisclosureSEC source: 0001387131-21-008746 · medytox-form4_081721.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,057,652 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:15 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 70,000 | $10.69 | $748,062.00 |
DisclosureSEC source: 0001387131-21-008746 · medytox-form4_081721.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012,652 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:10 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 65,000 | $11.34 | $737,035.00 |
DisclosureSEC source: 0001387131-21-008661 · medytox-form4_081321.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,942,652 Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:10 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 49,714 | $10.98 | $545,715.55 |
DisclosureSEC source: 0001387131-21-008661 · medytox-form4_081321.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877,652 Read SEC document |
| August 13, 2021 Filed Feb 6, 2023 21:18 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 14,043 | $11.11 | $156,064.07 |
DisclosureSEC source: 0001387131-23-001468 · ownership.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,296,543 F1 · date: Inadvertently filed late due to an administrative error. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive. F4 · ownership.nature: The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 20:33 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 39,126 | $10.93 | $427,713.69 |
DisclosureSEC source: 0001387131-21-008519 · medytox-form4_081121.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,827,938 Read SEC document |
| August 12, 2021 Filed Feb 6, 2023 21:18 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 23,000 | $10.99 | $252,774.60 |
DisclosureSEC source: 0001387131-23-001468 · ownership.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,282,500 F1 · date: Inadvertently filed late due to an administrative error. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2. F4 · ownership.nature: The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:33 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock, $0.00001 par value per share | 26,160 | $10.77 | $281,737.97 |
DisclosureSEC source: 0001387131-21-008519 · medytox-form4_081121.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,788,812 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.